Most DNA is inside the cell’s nucleus. As a tumor grows, cells die and are replaced. The dead cells are broken down and their content, including DNA, is released into the bloodstream. Liquid biopsies (also interchangeable with circulating cell-free DNA or ctDNA) are fragments of DNA released by cells during apoptosis and necrosis, which circulate in the bloodstream.

For instance, the detection of ctDNA allows for personalized cancer surveillance based on an individual’s unique set of tumor mutations. As such, liquid biopsies are a practical alternative for investigating tumor-derived alterations.

• Minimally invasive: reduces the need for a biopsy or rebiopsy
• Reduced patient risk: much less painful than a solid tumor biopsy, especially when performed during advanced cancer stages
• Tissue continues to be the issue: 1/5 patients often do not have enough tissue to perform next-generation sequencing (NGS) broad panel assays
• Easy: requires less staff especially when compared to biopsy (fine needle aspirate, core needle aspiration) or surgical resection
• Patient comfort: outpatient consult blood sampling
• Monitor: sometimes used to monitor tumor burden longitudinally

Cerba Research is happy to support your trials with our liquid biopsy capabilities and expertise, from an already existing ctDNA-based panel to the customization of a panel and the delivery of a medical-grade report, we are your trusted partner throughout your clinical trial journey.